Noveris Health Sciences Inc.

Noveris Health Sciences Inc. is a biotechnology company focused on the research, development, and commercialization of psilocybin products for mental health conditions. The company's primary therapeutic areas are nicotine addiction and post-traumatic stress disorder. Noveris Health Sciences Inc. is also developing specific compounds, MYCO-005, MYCO-006, and MYCO-007, which are MDMA and psilocybin analogs. The company collaborates with Applied Pharmaceutical Innovation on pharmaceutical drug discovery, research, and development, specifically targeting empathogenic and entactogenic compounds. Incorporated in 2013, Noveris Health Sciences Inc. is headquartered in Vancouver, Canada. The company was previously known as Mydecine Innovations Group Inc. and officially changed its name to Noveris Health Sciences Inc. in February 2026.